yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital.
.
cambridge's bluebird bio licenses delivery tech to novartis, gsk
. the software identified and measured a marker of svd and then gave a score indicating how severe the disease was ranging from mild to severe.
.